Logo

Coherus BioSciences Reports the Launch of Loqtorzi (toripalimab-tpzi) across the United States to Treat Nasopharyngeal Carcinoma (NPC)

Share this
Coherus

Coherus BioSciences Reports the Launch of Loqtorzi (toripalimab-tpzi) across the United States to Treat Nasopharyngeal Carcinoma (NPC)

Shots:

  • Loqtorzi is indicated in combination with cisplatin & gemcitabine for the 1L treatment of adults with metastatic or recurrent locally advanced NPC & as a monotx. for adults with recurrent/unresectable/metastatic NPC
  • In Dec 2023, the NCCN committee preferred Loqtorzi as a category 1 treatment option in combination with cisplatin & gemcitabine based on the results from the P-III (JUPITER-02) & P-II (POLARIS-02) trials
  • In the P-III (JUPITER-02) trial, Loqtorzi +CT significantly improved PFS & reduced the risk of disease progression or death by 48% along with an improved OS. In the P-II (POLARIS-02) study Loqtorzi showed durable anti-tumor activity in recurrent/metastatic NPC patients with an ORR of 20.5%, DCR of 40% & mOS of 17.4mos.

Ref: Coherus Image: Coherus

Related News:- Coherus and Junshi Biosciences Received the US FDA’s Approval for Loqtorzi (toripalimab-tpzi) to Treat Nasopharyngeal Carcinoma (NPC)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions